Cantor Fitzgerald Predicts VERA FY2025 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Vera Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will earn ($2.22) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $107.00 target price on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.21).

VERA has been the subject of a number of other research reports. Guggenheim boosted their price target on Vera Therapeutics from $56.00 to $64.00 and gave the stock a "buy" rating in a report on Monday, October 28th. Wedbush boosted their target price on Vera Therapeutics from $30.00 to $38.00 and gave the stock a "neutral" rating in a research note on Friday, November 8th. Wells Fargo & Company started coverage on shares of Vera Therapeutics in a research note on Thursday, November 21st. They issued an "overweight" rating and a $70.00 price target on the stock. JPMorgan Chase & Co. upped their price objective on shares of Vera Therapeutics from $72.00 to $75.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Finally, Scotiabank started coverage on shares of Vera Therapeutics in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $60.00 target price on the stock. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $63.50.

Vera Therapeutics Price Performance

VERA traded up $0.32 during trading on Thursday, hitting $34.09. 1,004,760 shares of the stock traded hands, compared to its average volume of 762,569. The business has a 50 day moving average price of $43.12 and a 200 day moving average price of $40.93. The company has a market cap of $2.16 billion, a price-to-earnings ratio of -13.06 and a beta of 1.15. Vera Therapeutics has a twelve month low of $16.84 and a twelve month high of $51.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76.

Insider Activity

In other news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $43.07, for a total value of $753,725.00. Following the completion of the transaction, the chief executive officer now directly owns 85,942 shares of the company's stock, valued at approximately $3,701,521.94. This trade represents a 16.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Beth C. Seidenberg sold 15,000 shares of the company's stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $48.03, for a total value of $720,450.00. Following the sale, the director now owns 131,553 shares in the company, valued at approximately $6,318,490.59. The trade was a 10.24 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 67,500 shares of company stock valued at $3,026,075. Company insiders own 21.70% of the company's stock.

Institutional Investors Weigh In On Vera Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Holocene Advisors LP grew its position in shares of Vera Therapeutics by 8.8% during the 3rd quarter. Holocene Advisors LP now owns 1,954,528 shares of the company's stock worth $86,390,000 after buying an additional 158,451 shares during the period. Geode Capital Management LLC boosted its stake in Vera Therapeutics by 2.1% during the third quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company's stock worth $44,415,000 after acquiring an additional 20,223 shares in the last quarter. Marshall Wace LLP grew its holdings in Vera Therapeutics by 9.2% in the second quarter. Marshall Wace LLP now owns 524,578 shares of the company's stock worth $18,979,000 after purchasing an additional 44,059 shares during the period. Jennison Associates LLC increased its stake in Vera Therapeutics by 1.3% in the third quarter. Jennison Associates LLC now owns 447,098 shares of the company's stock valued at $19,762,000 after purchasing an additional 5,936 shares in the last quarter. Finally, Lord Abbett & CO. LLC raised its holdings in shares of Vera Therapeutics by 41.1% during the third quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company's stock valued at $18,830,000 after purchasing an additional 124,197 shares during the period. 99.21% of the stock is currently owned by institutional investors.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.